Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

GeneCraft Inc.

Status and phase

Not yet enrolling

Phase 1

Conditions

Non-Small Cell Lung Cancer

Treatments

Drug: RX001

Study type

Interventional

Funder types

Industry

Identifiers

NCT06934590

GC-LCP1001

Details and patient eligibility

About

This is an open-label, dose-escalation Phase I study to evaluate the safety and tolerability of RX001 monotherapy in patients with advanced KRAS mutant NSCLC. Subjects aged ≥19 years with advanced NSCLC with KRAS mutations will be enrolled. Based on the investigator's judgment of the lung tumor location, RX001 will be administered as a single intratumoral treatment via bronchoscopy or CT-guided percutaneous injection. Additionally, after conducting safety, tolerability, and preliminary anti-tumor efficacy assessments for all subjects up to Week 12 (D84) following IP administration, the collected data will be reviewed by the SRC for a comprehensive evaluation. If the IP is designated for long-term follow-up studies, monitoring for malignant tumor formation and other SAEs specified by the Ministry of Food and Drug Safety (MFDS) will be conducted for a minimum of 5 years.

Enrollment

18 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults aged ≥19 years, male or female
Subject with histologically and/or cytologically confirmed, unresectable advanced NSCLC for radical cure that are confirmed as PD for the standard of care currently known to have clinical benefits, or for which no currently available standard of care exists due to intolerance, ineligibility, treatment refusal, etc.
Subjects must have at least one evaluable and injectable lesion as assessed on CT images based on RECIST version 1.1.
Subjects with valid biopsy results documented the presence of KRAS mutation.
Subjects with an ECOG performance status of 0 or 1 and an expected survival of at least 12 weeks at the time of study participation.
Subjects with adequate hematologic and terminal organ function.
Subjects must voluntarily sign an informed consent form approved by the IRB. Subjects must have the willingness and ability to comply with all procedures required by the protocol.

Exclusion criteria

Subjects must not meet any of the following conditions:
Subjects with a history of or current comorbidities including:
1. Hematologic malignancies, such as lymphoma, or any other malignant tumors apart from the indication of this study.
2. Subjects with the cardiovascular conditions such as unstable angina and/or myocardial infarction within 1 year prior to screening
3. Subjects with the pulmonary baseline conditions:
4. Blood coagulation disorder
5. Active bleeding disorders (including gastrointestinal bleeding)
Subjects who have received antithrombotics, including antiplatelets or anticoagulants
Subjects who have received anticancer therapies within 28 days prior to trial participation, or who have not recovered or stabilized from all AEs caused by such treatments to baseline levels
Subjects who have received radical radiotherapy within 6 weeks prior to trial participation etc.
Subjects who have received live vaccines or attenuated vaccines within 4 weeks prior to study participation
Subjects with active HBV or HCV, or HIV positive
Subjects with severe infections requiring antibiotics, antifungal agents, or antiviral agents, or those with uncontrolled active infectious diseases
Subjects with any form of primary immunodeficiency or active autoimmune diseases
Subjects who have previously received intratumoral therapy for the target lesion
Ineligibility or inability to participate in the study at the investigator's discretion